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Structured abstract 
Background 
Currently colon cancer is staged with computed tomography (CT). However, 
magnetic resonance imaging (MRI) is superior in the detection of colorectal liver 
metastasis and MRI is standard in local staging of rectal cancer. Optimal (local) 
staging of colon cancer could become crucial in selecting patients for neo-
adjuvant treatment in the near future (FOXTROT trial).  
Objective 
The purpose of this study was to evaluate the diagnostic performance of MRI for 
local staging of colon cancer. 
Design 
Retrospective study. 
Settings 
Study Conducted at our institute. 
Patients 
In total 55 patients with biopsy proven colon carcinoma were included. 
Main outcome measures 
All patients underwent a MRI (1.5 Tesla; T2 and diffusion weighted imaging) of 
the abdomen and were retrospectively analysed by two blinded, independent 
readers. Histopathology after resection was the reference standard.  
Both readers evaluated tumor characteristics being; invasion through bowel wall ȋ ?Ȁ ?Ȍǡ ? ?Ȁvasion of 
surrounding organs (T3cd/T4), serosal involvement, extramural vascular 
invasion and malignant lymph nodes(N+). Inter-observer agreement was ȋɈȌǤ 
Results 
MRI had a high sensitivity (72-91%) and specificity (84-89%) in detecting T3/T4 
tumors (35/55) and a low sensitivity (43-67%) and high specificity (75-88%) in 
detecting T3cd/T4 tumors (15/55). For detecting serosal involvement and 
extramural vascular invasion MRI had a high sensitivity and moderate specificity 
and a moderate sensitivity and specificity in the detection of nodal involvement. 
Interobserver agreements were predominantly good, the more experienced 
reader achieved better results in the majority of these categories. 
Limitations 
Retrospective nature of study and moderate number of inclusions. 
Conclusion 
MRI has a good sensitivity for tumor invasion through the bowel wall, 
extramural vascular invasion and serosal involvement. Additionaly, together 
with its superior liver imaging, MRI might become the optimal staging modality 
for colon cancer. However, more research is needed to confirm this. 
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Introduction 
 
Distant and local staging of colon cancer is currently mainly performed with 
computed tomography (CT). However, according to a recent meta-analysis CT 
has a limited sensitivity of 75% for detecting liver metastasis1. 
At diagnosis, 15-23% of colorectal cancer (CRC) patients have liver metastasis2, 3. 
Detection is crucial because it means poor prognosis and a different clinical 
approach and treatment4. Multiple studies already demonstrated that magnetic 
resonance imaging (MRI) is superior to CT for the detection of liver metastasis1, 5. 
Both the introduction of diffusion-weighted imaging (DWI) and the use of liver-
specific hepatobiliary contrast agents have contributed to the superior results of 
MRI in detecting small liver lesions6, 7. 
Unlike in rectal cancer where local staging with imaging is crucial to determine 
the proper (neoadjuvant) treatment strategy, imaging in colon cancer is mostly 
used as a surgical roadmap. However, the role of imaging for local staging of 
colon cancer might emerge in the near future; several small studies and case 
reports showed additional value of neo-adjuvant treatment in locally advanced 
colon cancer8-12. Furthermore, a large multicenter study, FOXTROT13, is currently 
investigating the benefits of neo-adjuvant chemotherapy for patients with locally 
advanced colon cancer. If the FOXTROT trial confirms initial promising reports, 
neoadjuvant treatment in colon cancer patients will be adopted as standard 
therapy, just like in rectal cancer patients. If so, preoperative imaging will 
become a crucial tool to select patients for neo-adjuvant treatment. In the 
FOXTROT trial, CT is used to detect locally advanced colon cancer and thus 
eligibility for neo-adjuvant treatment. Nonetheless a recent meta-analysis14 
showed disappointing results for staging colon cancer with CT. In our opinion 
this means other modalities such as MRI should be at least considered. MRI is 
well established in local staging of rectal cancer due to its superior results 
compared to CT15. However, little is known about the local staging of colon 
cancer with MRI. If MRI is able to accurately stage colon tumors, it might be the 
ideal imaging tool for simultaneous local and distant staging. Therefore, the aim 
of this study was to evaluate the diagnostic performance of MRI for local staging 
of colon cancer patients. 
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Materials and methods 
This study was approved by the institutional review board. Informed consent 
was waived because of the retrospective nature of the study.  
 
Patient population 
Eighty consecutive patients were diagnosed with colon cancer at [blinded] from 
April 2014 until May 2015. Inclusion criteria were as follows: (a) biopsy-proven 
adenocarcinoma of the colon (with a distal tumor margin > 15 cm from the 
anorectal junction, measured at endosccopy), (b) preoperative staging with MRI, 
(c) availability of histopathological results after surgical resection of the colon. 
Twenty-five patients were excluded for the following reasons: no surgical 
resection (only a polypectomy with tumor free margin was performed during 
colonoscopy n=11), inoperable disease (n=8), benign outcome (e.g. adenoma, 
these patients received a MRI before the definitive histopathological result was 
available) at histopathology (n=5) and insufficient MR image quality due to 
severe motion artefacts (n=1). This left a total of 55 patients that met the final 
inclusion criteria. 
 
MR imaging protocol 
Imaging was performed with a 1.5T MRI (Ingenia, Philips Medical Systems, Best, 
The Netherlands) using a phased array body coil. Patients were placed in feet 
first supine position. Bowel preparation consisted of  ? ?
MR examination. To minimize peristaltic movements, patients received an 
intravenous bolus injection before the MR examination, of 20 mg Hyoscine 
Butylbromide (Buscopan®, Boehringer Ingelheim BV, Ingelheim, Germany) 
before the start of the MR examination, or 1mg of glucagon (GlucaGen® Novo 
Nordisk, Bagsværd, Denmark) in case of a contra-indication to receive Hyoscine 
Butylbromide. The scan protocol consisted of a MR liver protocol combined with 
an additional MR colon protocol covering the whole abdomen. This additional 
colon protocol consisted of T2-weighted turbo spin echo (TSE)  sequences (2 
axial stacks and 1 coronal stack), an axial diffusion-weighted sequence (acquired 
in 3 stacks; b1000 being the highest b-value) and a pre- and post-contrast T1 
Thrive sequence (in coronal plane). The echo time (TE) and repetition time (TR) 
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were 80ms and 5596ms for T2 and 65ms and 3808ms for DWI respectively. The 
slice thickness for T2 and DWI was 3mm and 8mm respectively. The minimal 
slice gap for T2 and DWI was 3mm and 0mm respectively. Field of view of 390 x 
390 mm for T2 and 380 x 290 mm for DWI. Acquisition matrix for the T2 and 
DWI was 392 x 392 and 152 x 115 with an acquisition voxel size (mm) of 0.99 x 
0.99 x 3.00 and 2.50 x 2.51 x 8.00 respectively. The number of excitations (NEX) 
were 2 for T2 and 4 for DWI. Acquisition time of the MR colon protocol was 18 
minutes. Total acquisition time of the colon + liver protocol was 50 minutes. 
 
Image Evaluation  
Two readers (reader 1 with 12 and reader 2 with 8 years experience in reading 
abdominal MRI) independently assessed the MR colon images to evaluate the 
local tumor status. The liver images were used for further clinical staging of 
distant metastases (outside the scope of this study). The readers were blinded 
for the surgical outcome and histological results. Both readers scored the 
following items: [1] location of the tumor (caecum, ascending colon, transverse 
colon, descending colon and sigmoid);[2] tumor stage (T1-2 vs T3-4); [3] in case  ? ?ǡȋȌǡ ? ?
was classified as a T3ab tumor and an EMD of  >5mm was classified as a T3cd 
tumor. [4] in case of a T4 tumor: the presence of serosal involvement and/or 
adjacent organ invasion; [5] extramural venous invasion (EMVI); and [6]lymph 
nodes status (N0/N+). The readers evaluated the abovementioned items by use 
of a confidence level score; 0 = definitely not, 1 = probably not, 2 = uncertain, 3 = 
probably yes, 4 = definitely yes). All imaging datasets (T2-weighted, DWI, non-
enhanced and contrast-ȌǯǤ 
 
Image assessment criteria 
The criteria used for determining the T-stage were based on the AJCC 5th TNM-
classification, because this edition is still used in [blinded] and other European 
countries (e.g. United Kingdom). For positive nodal involvement the criteria 
were a short axis diameter of 8 mm or more and/or a cluster of 3 or more lymph 
nodes with a short axis diameter of >5 mm. Extramural venous invasion (EMVI) 
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was defined as direct invasion of the tumor in a vascular structure, serpiginous 
vessels and/or irregular aspect of vessel wall near the tumor site16. 
 
Statistical analyses 
Descriptive statistics were used for the assessment of baseline characteristics.  
For diagnostic performance the following outcomes were evaluated:  T-stage 
(T1/T2 vs T3/T4 and T1-T3ab vs T3cd/T4), serosal involvement, EMVI and 
nodal involvement. The diagnostic performance of MRI for the abovementioned 
outcomes was evaluated by means of receiver operator characteristics (ROC) 
curves for which areas under the ROC curve (AUC) with 95% confidence 
intervals were calculated. Sensitivity, specificity with 95% confidence intervals 
were calculated by 2x2 contingency tables based on the confidence level scores. 
Cut-off for confidence level scores was set between 2 and 3 before the onset of 
the study. Analyses were performed with SPSS® software version 22.0 (IBM 
corporation, Armonk, New York, U.S.A). Inter-observer agreement was compared 
using quadratic weighted kappa statistics and was categorized as poor 
agreement, fair, moderate, good and very good agreement according to kappa (Ɉ) 
values <0.20, 0.21-0.40, 0.41-0.60, 0.61-0.80 and 0.81-1.00, respectively.  
 
Reference standard 
Surgery was performed using standard techniques17. The resected specimens 
were processed using standard histologic protocol18. All specimens were 
evaluated by a senior pathologist with 10 years of experience in gastrointestinal 
pathology.  
 
Results 
Patient and tumor characteristics 
The final study population consisted of 55 patients (23 female, 32 male) with a 
median age of 69 years (range: 34Ȃ84 years). On average, surgery was 
performed 22 days (range of 3-51 days) after the staging MRI. In 50 out of 55 
patients  ?12 lymph nodes were harvested. In 5 patients <12 lymph nodes were 
harvested with a minimum of 6 resected lymph nodes. A tumor free resection 
margin (i.e. R0 resection) was achieved in all of the included patients. 
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Detailed tumor characteristics are given in Table 1. 
 
Diagnostic performance of MRI 
The results as stated below are summarized in table 2 and ROC curves results 
are presented in table 3.  
 
Tumor location 
Both readers correctly identified the location of the tumor in each patient. Ten 
tumors were located in the caecum, fifteen in the ascending colon, three in the 
transverse colon, seven in the descending colon and twenty in the sigmoid. 
Interobserver agreement between both readers was perfect (Ɉ=1.0). 
 
Tumor stage  
Area under the curve (AUC) for differentiating between T1-2 and T3-4 tumors 
was 0.88 (95%CI 0.77-0.99) for reader 1 and 0.85 (95%CI 0.74-0.96) for reader 
2. The sensitivity and specificity for detecting T3-T4 tumors were 91% (95%CI 
76-98%) / 84% (95%CI 60-96%) for reader 1 and 72% (95%CI 50-87%) / 89% 
(95%CI 65-98%) for reader 2. In patients with a T3 tumor, the sensitivity and 
specificity for detecting T3cd/T4 tumors were 40% (95%CI 17-67%) and 88% 
(95%CI 65-98%) for reader 1 and 60% (95%CI 33-83%)and 75% (95%CI 58-
87%) for reader 2.   
Interobserver agreement between both readers was good (Ɉ=0.72) for the 
differentiation between T1-2 vs T3-4 tumors, and moderate (Ɉ=0.55) for the 
differentiation of T3cd/T4 tumors. 
 
Serosal  
The AUC for detecting serosal involvement was 0.88 (95%CI 0.78-0.98) for 
reader 1 and 0.72 (95%CI 0.51-0.93) for reader 2. The sensitivity and specificity 
for detecting serosal involvement were 88% (95%CI 47-99%)/74% (95%CI 59-
86%) for reader 1 and 68% (95%CI 43-86%)/64% (95%CI 46-79%) for reader 2 
(table 2).  
 
Interobserver agreement between both readers was good (Ɉ=0.62). 
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Nodal status  
The sensitivity and specificity for detecting nodal involvement (N0 versus N+) 
were 47% (95%CI 25-71%)/86% (95%CI 70-95%) for reader 1 and 68% 
(95%CI 43-86%)/64% (95%CI 46-79%) for reader 2 (table 2).  
Interobserver agreement between both readers was moderate (Ɉ=0.60). 
 
Extramural venous invasion  
The AUC for detecting EMVI was 0.77 for both readers (95%CI 0.63-0.91 for 
reader 1 and 0.63-0.92 for reader 2). Both readers had a high sensitivity of 100%  
(95%CI 60-100%) and 88% (95%CI 47-99%) and a moderate specificity (62% 
(95%CI 46-75%) and 70%(95%CI 55-82%) in detecting EMVI respectively. 
Interobserver agreement between both readers was moderate (Ɉ=0.60). 
 
Discussion  
The aim of this study was to evaluate the diagnostic performance of MRI for local 
staging of colon cancer patients. Our findings show that MRI is able to accurately 
detect tumors with invasion through the bowel wall. In addition, MRI shows 
promising results for more recently adopted risk factors such as serosal 
involvement and EMVI. This means that, together with the already known 
superior results for the detection of small liver metastasis, MRI could become the 
most optimal local and distant staging modality for colon cancers. 
 
MRI showed accurate results in detecting tumor invasion through the bowel 
wall, with a high sensitivity and specificity (Table 2). Especially the specificity 
seems higher compared with a recent meta-analysis14 on staging of colon cancer 
with CT, where the summary sensitivity and specificity estimates for detecting 
tumor invasion beyond the bowel wall (T3-T4) with CT were 90% and 69% 
respectively, it should be noted however, the 95% confidence intervals do 
overlap for both the sensitivity and specificity (table 414, 19-21). The seemingly 
higher specificity of MRI for colon cancer can probably be explained by the 
superior soft tissue contrast of MRI. Only one study is comparable to ours in this 
category, it is a very recent study by Hunter et al.19 which demonstrated a lower 
sensitivity and specificity compared with our results (Table 4). This means that 
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more research is needed to define the role of MRI for colon cancer staging.  
Although it is not the focus of our study, diffusion weighted imaging (DWI) was 
especially useful for locating the colon tumor (as shown in figure 1A). The high 
signal on DWI made it easier to detect small colon tumors. 
 
The detection of T3cd/T4 tumors remains a problem with MRI. In our study, the 
low sensitivity (40-60%) indicates that the EMD is mainly underestimated and 
therefore T3cd/T4 tumors are understaged, possibly due to microscopic tumor 
expansion, which is not detectable with MRI. 
Disappointing results in detecting T3cd/T4 tumors were also found for CT in a 
recent meta-analysis14 with a higher summary sensitivity but lower specificity 
estimates compared with our results (Table 4). These low summary estimates 
might be caused by desmoplastic reaction being interpreted as tumor expansion, 
resulting in overstaging. A recent study by Rollven et al.20 conducted with MRI 
and CT, and scored by 2 observers, showed a higher sensitivity and specificity for 
both modalities with MRI being superior (Table 4). However, this study was 
relatively small (n=29) and was carried out by two very experienced observers 
(both dedicated abdominal radiologist with 6 and 18 years experience). In 
contrast, the study by Hunter et al. (which included 55 patients who received 
MRI only) shows much lower sensitivity and specificity compared to the results 
presented by Rollven et al. and our study (Table 4). Hence, further research is 
needed to fully understand the role of imaging for the detection of EMD. 
 
According to our results MRI has a good accuracy in detecting serosal 
involvement (AUC=0.85-0.88). The ability of MRI to rule out serosal involvement 
could provide clinicians with valuable information concerning operability and 
prognosis. Patients with serosal involvement (figure 1B) have a poorer five-year 
survival (24.3%) than those in whom it is absent (55.4%)22. The mediocre 
specificity could be explained by desmoplastic reaction involving the serosa or 
fascia, which may erroneously be interpreted as tumor expansion. To our 
knowledge there is no literature about the accuracy of CT in the detection of 
serosal involvement as defined in our study. 
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Results for detecting nodal involvement were mediocre for both readers. 
According to a recent meta analysis14, CT shows comparably disappointing 
results, with summary estimates for sensitivity and specificity of 71% and 67% 
respectively. In the pilot study for the FOXTROT trial (using CT) the accuracy 
was also disappointing with a good sensitivity of 83% but a low specificity of 
44%13. CT and MRI both seem unreliable in the detection of nodal involvement19, 
20. This fact is also well known in staging of rectal cancer23. Although lymph 
nodes are clearly visible diffusion weighted images (as shown in figure 1C), this 
does not necessarily represent metastatic involvement, as the high cellularity in 
lymph nodes causes a high DWI signal in benign lymph nodes as well24, 25. 
Several factors contribute to this low accuracy. Lymph node diameter is the most 
commonly used criterion but is not accurate for assessing lymph node metastasis 
in colon cancer26. Moreover, false negative results are caused by microscopic 
metastasis in lymph nodes with a normal diameter and false positive results are 
caused by benign lymph nodes that are enlarged due to inflammation. This is an 
important diagnostic problem, because distant nodal involvement along the 
mesenteric arteries may justify a more extensive hemicolectomy. Interestingly, 
new intravenous contrast agents such as gadofosveset show promising results 
for nodal staging in rectal cancer27. Further research is warranted because this 
may improve the detection of nodal involvement in colon cancer patients.   
 
In detecting EMVI, our results show a very high sensitivity. The ability of MRI to 
rule out EMVI provides clinicians with valuable information, because EMVI 
results in a poorer five-year survival (25.0%) than if EMVI is absent (57.4%)22. A 
recent large study21, which used CT to detect EMVI, described a low sensitivity 
and mediocre specificity (Table 4). Furthermore the study by Rollven et al. 20 
confirms the superior accuracy of MRI for EMVI while the study by Hunter et al.19 
reports a low sensitivity with a good specificity (table 4). Nonetheless it seems 
MRI is superior in the detection of EMVI. The specificity in our study was 
mediocre, which could be explained by traction on the vessels and/or thrombus 
formation due to altered hemodynamics caused by local inflammation, however 
this theory needs to be confirmed by other studies. 
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Both readers have experience with reading MRI of the abdomen especially MRI 
of the rectum, however reader 1 has a four years advantage and is more accurate 
in the majority of the categories (table 2). It seems experience does translate into 
better results however it should be noted that this difference is minor in most 
categories and the interobserver agreement was at least moderate in all 
categories. 
 
Limitations 
Our study has some limitations. Firstly, the retrospective nature of this study. 
Secondly, a total number of 55 patients were included in this pilot study. Large 
multicenter trials are needed to define the role of MRI for dedicated colon 
staging.  
 
Clinical impact 
Compared to previous literature on CT our study shows that MRI seems to 
perform as well as CT in local staging, with the added benefit that it has the 
potential to be more accurate in detecting prognostic factors such as EMVI. An 
additional important advantage of MRI is its superiority in detecting small liver 
metastases with the evaluation of the colon tumor in one imaging session1. The 
most recent EURECCA expert guidelines advise MRI of the liver28 in the 
preoperative staging of colorectal cancer.  This would mean that the MR 
sequences for local staging of the colon tumor can be performed in the same MR 
imaging session of the liver. This combined approach could result in the most 
optimal abdominal staging tool for colon cancer patients. Another advantage of 
this approach is the avoidance of ionizing radiation and nephrotoxic contrast 
agents.  
 
Conclusion  
Our study shows that MRI has the potential to become a valuable tool in 
preoperative staging of colon cancer, with results that are comparable to CT in 
the detection of important prognostic factors such as tumor and nodal staging. In 
addition, MRI seems to have a high sensitivity for additional risk factors, such as 
serosal involvement and EMVI. Combined with its known superiority in 
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detecting liver metastasis, MRI could become the most optimal abdominal 
staging method for colon cancer patients. However, due to the limited research 
on this topic, more research is needed to confirm these promising results. 
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Figure and table legend 
 
Figure 1A. 
T2 weighted sequence (left) and corresponding b1000 diffusion-weighted 
images (right), show a small T2 tumor in the ascending colon (arrow). This small 
tumor could easily be missed on T2-weighted images. However it is clearly 
depicted on diffusion weighted images.  
 
 
Figure 1B. 
T2 weighted image of a patient with a tumor of the ascending colon (arrow). The 
tumor grows through the bowel wall. Both readers accurately identified the 
serosal involvement (black arrowheads), which was nicely depicted with MRI 
and the tumor was staged as a T4 tumor. This was confirmed by histopathology.  
 
 
Figure 1C. 
T2 weighted sequence (left) and corresponding b1000 diffusion-weighted 
imaging (right) show an example of a small T3 tumor in the ascending colon 
(arrowhead) and local, enlarged lymph nodes (arrows). Note the conspicuity of 
these lesions on DWI, aiding in the detection of the tumor and lymph nodes.  
 
 
Table 1. 
Patient and tumor characteristics. Asc. Colon = Ascending colon, Colon Tr. = 
Colon transversum, Des. Colon = Descending colon. 
 
Table 2.  
Study results. Serosa +/- = detection of serosal involvement. N +/- = detection of 
nodal involvement. EMVI +/- detection of extramural vascular involvement. 
Sens.=sensitivity, Spec.=specificity. The numbers between the brackets represent 
the 95% confidence interval (CI). 
 
Table 3.  
Receiver operating characteristic (ROC) curves results. AUC = Area under the 
curve as measured with a ROC curve. The numbers between the brackets 
represent the 95% confidence interval (CI). Serosa +/- = detection of serosal 
involvement. N +/- = detection of nodal involvement. EMVI +/- detection of 
extramural vascular involvement. 
 
Table 4. 
Overview of comparable studies and results. The numbers between the brackets 
respresent the 95% confidence intervals. *This meta-analysis presents the 
accuracy for staging of colon cancer with computed tomography (CT), and 
included both the studies by Rollven20 et al. and Dighe21 et al. except for EMVI 
which is given separately. 
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Table 1 
 
Patient gender Female Male 
   
 
23 32 
   
      Patient age Median Range 
   
 
69 years 34-84 years 
   
      Tumor location Caceum Asc. Colon Colon Tr. Des. Colon Sigmoid 
 
10 15 3 7 20 
      Tumor stage T1 T2 T3ab T3cd T4 
 
4 15 19 9 8 
      Serosal inv. negative positive 
   
 
47 8 
   
      Nodal stage N0 N+ 
   
 
36 19 
   
      EMVI negative positive 
   
 
38 17 
   
      Time between MRI Average Range 
   and surgery 22 days 3-51 days 
    
7DEOH
Table 2 
 
 Reader 1 Reader 2 
Tumor 
stage 
Sens. Spec. Sens. Spec. 
T1/T2 vs 
T3/T4 
91% 
(76-98%) 
84% 
(60-96%) 
72% 
(50-87) 
89% 
(65-98) 
T1-T3ab vs 
T3cd/T4 
40% 
(17-67%) 
88% 
(73-95%) 
60% 
(33-83%) 
75% 
(58-87%) 
Serosa 
 +/- 
88% 
(47-99%) 
74% 
(59-86%) 
75% 
(36-96%) 
72% 
(57-84%) 
Nodal stage 
+/- 
47% 
(25-71%) 
86% 
(70-95%) 
68% 
(43-86%) 
64% 
(46-79%) 
EMVI  
+/- 
100% 
(60-100%) 
62% 
(46-75%) 
88% 
(47-99%) 
70%  
(55-82%) 
7DEOH
Table 3 
 
  Reader 1 Reader 2 
Tumor 
stage 
AUC 
 
AUC 
 
T1/T2 vs 
T3/T4 
0.88 
(0.77-0.99) 
0.85 
(0.74-0.96) 
Serosa 
+/- 
0.88 
(0.78-0.98) 
0.72 
(0.51-0.93) 
Nodal stage 
+/- 
0.73 
(0.58-0.88) 
0.63 
(0.47-0.80) 
EMVI  
+/- 
0.77 
(0.63-0.91) 
0.77 
(0.62-0.92) 
7DEOH
 Table 4 
 
Modality T3-T4 T3cd-T4 N+ EMVI 
MRI Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity 
Hunter et 
al.19 
74% 
(60-85%) 
58% 
(32-81%) 
67% 
(45-83%) 
79% 
(63-90%) 
26% 
(13-46%) 
81% 
(64-91%) 
63% 
(41-81%) 
80% 
(64-90%) 
42% 
(28-57%) 
83% 
(55-95%) 
43% 
(24-63%) 
94% 
(81-98%) 
35% 
(19-55%) 
74% 
(57-86%) 
26% 
(12-49%) 
91% 
(78-97%) 
Rollven et 
al.20 
 
N/A 
 
77% 
(50Ȃ92%) 100% (81-100%) 86% (49Ȃ97%) 68% (47Ȃ84%) 75% (41Ȃ93%) 84% (62Ȃ95%) 
92% 
(67Ȃ99%) 94% (72Ȃ99%) 86% (49Ȃ97%) 64% (43Ȃ80%) 75% (41Ȃ93%) 79% (57Ȃ92%) 
our results 
91% 
(76-98%) 
84%  
(60-96%) 
40% 
(17-67%) 
88% 
(73-95%) 
47% 
(25-71%) 
86% 
(70-95%) 
100% 
(60-100%) 
62% 
(46-75%) 
72% 
(50-87%) 
89% 
(65-98%) 
60% 
(33-83%) 
75% 
(58-87%) 
68% 
(43-86%) 
64% 
(46-79%) 
88% 
(47-99%) 
70%  
(55-82%) 
CT 
 Nerad et 
al.*14 
90%  
(83-95%)  
69%  
(62-75%)  
77%  
(66-85%)  
70%  
(53-83%) 
71%  
(59-81%)  
67%  
(46-83%)  
 Rollven et 
al.20  
     
38%  
(14Ȃ 69%)  95%  (75Ȃ99%)  
       
38% 
(14-69%) 
79%  
(57Ȃ92%)  
Dighe et al.21       
47% 
(32-63%) 
68% 
(56-79%) 
7DEOH
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